Skip to main content

Advertisement

SpringerLink
Log in

Juvenile dermatomyositis update

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Recent studies involving juvenile dermatomyositis indicate that the majority of affected children have symptoms suggestive of infection prior to disease onset, damage to skin and muscle each have a distinct pathophysiology, certain urinary muscle metabolites may be useful laboratory markers, and methotrexate used as first line therapy with corticosteroids is associated with greater height velocity and smaller increase in body mass index.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Pachman LM, Lipton R, Ramsey-Goldman R, et al.: History of infection before the onset of juvenile dermatomyositis: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Research Registry. Arthritis Rheum 2005, 53:166–172. This study documents the increased incidence of infectious symptoms prior to onset of JDM in a majority of patients.

    Article  PubMed  Google Scholar 

  2. Mamyrova G, Rider LG, Haagenson L, et al.: Parvovirus B19 and onset of juvenile dermatomyositis. JAMA 2005, 294:2170–2171.

    Article  PubMed  CAS  Google Scholar 

  3. Minetti C, Gattorno M Repetto S, et al.: Chemokine receptor CCR7 is expressed in muscle.bers in juvenile dermatomyositis. Biochem Biophys Res Commun 2005, 333:540–543.

    Article  PubMed  CAS  Google Scholar 

  4. Sakuta R, Murakami N, Jin Y, et al.: Diagnostic signifi- cance of membrane attack complex and vitronectin in childhood dermatomyositis: J Child Neurol 2005, 20:596–602.

    Article  Google Scholar 

  5. Tomono N, Mori M, Nakajima S, et al.: HLA-DRB1*15021 is the predominant allele in Japanese patients with juvenile dermatomyositis. J Rheumatol 2004, 31:1847–1850.

    PubMed  CAS  Google Scholar 

  6. Chung YL, Rider LG, Bell JD, et al.: Muscle metabolites, detected in urine by proton spectroscopy, correlate with disease damage in juvenile idiopathic inflammatory myopathies. Arthritis Rheum 2005, 53:565–570.

    Article  PubMed  Google Scholar 

  7. Maillard SM, Jones R, Owens CM, et al.: Quantitative assessments of the effects of a single exercise session on muscles in juvenile dermatomyositis. Arthritis Rheum 2005, 53:558–564.

    Article  PubMed  Google Scholar 

  8. Takken T, van der Net J, Helders PJ: The reliability of an aerobic and an anaerobic exercise tolerance test in patients with juvenile onset dermatomyositis. J Rheumatol 2005, 32:734–739.

    PubMed  Google Scholar 

  9. Smith RL, Sundberg J, Shamiyah E, et al.: Skin involvement in juvenile dermatomyositis is associated with loss of end row nailfold capillary loops. J Rheumatol 2004, 31:1644–1649. This study demonstrates the association of nailfold abnormalities and skin involvement, but lack of association with severity of muscle disease.

    PubMed  Google Scholar 

  10. Fathalla BM, Miller LC, Bubolz B, Schaller JG: Prolonged QTc interval and juvenile dermatomyositis. Clin Exp Rheumatol 2004, 22:788–789.

    PubMed  CAS  Google Scholar 

  11. Akikusa JD, Tennankore, Levin AV, Feldman BM: Eye.ndings in patients with juvenile dermatomyositis. J Rheumatol 2005, 32:1986–1991.

    PubMed  Google Scholar 

  12. Stock S, Ignatiev K, Lee P, et al.: Pathological calcification in juvenile dermatomyositis (JDM):microCT and synchrotron x-ray diffraction reveal hydroxyapatite with varied microstructures. Connect Tissue Res 2004, 45:248–256.

    Article  PubMed  CAS  Google Scholar 

  13. Alsufyani KA, Ortiz-Alvarez O, Cabral DA, et al.: Bone mineral density in children and adolescents with systemic lupus erythematosus, juvenile dermatomyositis, and systemic vasculitis: relationship to disease duration, cumulative corticosteroid dose, calcium intake, and exercise. J Rheumatol 2005, 32:729–733.

    PubMed  CAS  Google Scholar 

  14. Ramanan AV, Campbell-Webster N, Ota S, et al.: The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. Arthritis Rheum 2005, 52:3570–3357. Although a retrospective study, the data demonstrates the benefit of early use of methotrexate combined with more rapid corticosteroid tapering.

    Article  PubMed  CAS  Google Scholar 

  15. Ambler GR, Chaitow J, Rogers M, et al.: Rapid improvement of calcinosis in juvenile dermatomyositis with alendronate therapy. J Rheumatol 2005, 32:1837–1839.

    PubMed  Google Scholar 

  16. Huber A, Feldman BM: Long-term outcomes in juvenile dermatomyositis: how did we get here and where are we going? Curr Rheum Rep 2005, 7:441–446.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, University of Kansas Medical Center, 66160-7330, Kansas City, KS, USA

    Carol B. Lindsley MD

Authors
  1. Carol B. Lindsley MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carol B. Lindsley MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lindsley, C.B. Juvenile dermatomyositis update. Curr Rheumatol Rep 8, 174–177 (2006). https://doi.org/10.1007/s11926-996-0022-6

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-996-0022-6

Keywords

Search

Navigation